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IL-8 enhance invasive activity of LoVo cells induced
by PRL-3 in a KCNN4 channel-dependent manner
Heyang Xu†, Wei Lai†, Yang Zhang†, Lu Liu, Xingxi Luo, Yujie Zeng, Heng Wu, Qiusheng Lan and Zhonghua Chu*Abstract
Background: Tumor-associated macrophages (TAMs) are known to promote cancer progression and metastasis
through the release of a variety of cytokines. Phosphatase of regenerating liver (PRL-3) has been considered as a
marker of colorectal cancer (CRC) liver metastasis. Our previous research suggests that PRL-3 can enhance the
metastasis of CRC through the up-regulation of intermediate-conductance Ca2+-activated K+ (KCNN4) channel,
which is dependent on the autocrine secretion of tumor necrosis factor-alpha (TNF-α). However, whether TAMs
participate in the progression and metastasis of CRC induced by PRL-3 remains unknown.
Methods: We used flow cytometry, coculture, western blotting, invasion assays, real-time quantitative PCR, chromatin
immunoprecipitation, luciferase reporter assays, and immunofluorescence staining to determine the effect of TAMs on
the ability of PRL-3 to promote invasiveness of CRC cells.
Results: In this study, we found that TAMs facilitated the metastasis of CRC induced by PRL-3. When TAMs were
cocultured with CRC cells, the expression of KCNN4 was increased in TAMs and the invasion of CRC cells was
enhanced. Furthermore, cytokines that were secreted by TAMs, such as IL-6 and IL-8, were also significantly increased.
This response was attenuated by treating TAMs with the KCNN4 channel-specific inhibitor, 1-[(2-chlorophenyl)
diphenylmethyl]-1H-pyrazole (TRAM-34), which suggested that KCNN4 channels may be involved in inducing the
secretion of IL-6 and IL-8 by TAMs and improving CRC cell invasiveness. Moreover, the expression of KCNN4
channels in TAMs was regulated through the NF-κB signal pathway, which is activated by TNF-α from CRC cells.
Immunofluorescence analysis of colorectal specimens indicated that IL-6 and IL-8 double positive cells in the
stroma showed positive staining for the TAM marker CD68, suggesting that TAMs produce IL-6 and IL-8. Increased
numbers of these cells correlated with higher clinical stage.
Conclusions: Our findings suggested that TAMs participate in the metastasis of CRC induced by PRL-3 through the
TNF-α mediated secretion of IL-6 and IL-8 in a paracrine manner.
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Immune cells infiltrate all neoplastic lesions, and to-
gether, the immune cells and tumor cells constitute the
tumor microenvironment. Such immune cells were pre-
viously thought to function in the defense response
against the tumor [1]. However, recently, increasing
evidence indicates that tumor-associated inflammatory* Correspondence: sumschuzhonghua@hotmail.com
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unless otherwise stated.cells may enhance tumor progression, and among these
cells, macrophages play the most important role [2].
Macrophages can alter their profiles such that they be-
come M1 or M2 macrophages according to the tumor
microenvironment. It has been shown that M2 macro-
phages are a type of tumor-associated macrophage (TAM)
[3]. TAMs can promote tumor cell growth and metastasis,
and recent research has indicated that TAMs can stimu-
late colorectal cancer cell invasion by upregulating matrix
metalloproteinase (MMP) expression and activating epi-
dermal growth factor receptor (EGFR) [4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tyrosine phosphatase, has been demonstrated to play an
important role in colorectal cancer progression and me-
tastasis [5]. PRL-3 is significantly elevated (>90%) in me-
tastases and moderately elevated (25–45%) in primary
colorectal cancer tumor. Moreover, the expression of
PRL-3 in primary tumors indicated their tendency to-
ward liver metastasis [6]. Our previous studies have
demonstrated that PRL-3 can promote the proliferation
and metastasis of tumor cells through the autocrine se-
cretion of tumor necrosis factor-alpha (TNF-α), which
induces intermediate-conductance Ca2+-activated K+
(KCNN4) channel expression by activating the NF-κB
signaling pathway [7]. Previous studies also revealed
that TNF-α contributed to tumor progression in a para-
crine manner. Because TNF-α secreted from tumor cells
and/or macrophages can affect the phenotype of these cells
in a paracrine and/or autocrine manner, we hypothesize
that colorectal cancer cells may interact with TAMs in the
microenvironment and alter the cytokine profile of TAMs
to promote tumor progression and metastasis through
TNF-α, the secretion of which is stimulated by PRL-3 in a
paracrine manner.
Interleukin-6 (IL-6) is a potent pleiotropic cytokine
that is predominantly produced by monocytes and mac-
rophages during chronic inflammation [8]. IL-6 has been
shown to be involved in tumor progression and metasta-
sis through STAT3 signaling pathways [9]. Moreover, the
level of IL-6 is positively correlated with poor prognosis
in different cancers. In addition to IL-6, interleukin-8
(IL-8) is also a known proinflammatory cytokine [10].
Extensive studies have demonstrated that the levels of
IL-8 and its receptor CXCR2 are significantly increased
in colorectal cancer (CRC) cells, and that these proteins
play an important role in tumor development [11]. Simi-
larly, the expression of IL-8 is correlated with tumor size
and tumor stage. However, the question of whether IL-6
and IL-8 are involved in the metastasis of CRC induced
by PRL-3 remains unclear.
In this study, we aimed to investigate whether TAMs
participate in the metastasis of CRC, which is induced
by PRL-3 in the tumor microenvironment. Our study re-
vealed that PRL-3 could induce the expression of IL-6
and IL-8 secreted by TAMs through TNF-α released by
CRC cells in a paracrine manner. Further study also re-
vealed that such regulation could be inhibited by block-
ing KCNN4 channels expressed by TAMs.
Methods
Reagents and antibodies
G418, PMA, and Lipofectamine2000 were purchased
from Sigma (St Louis, Missouri, USA). Fetal bovine serum
(FBS) was purchased from BioInd (Kibbutz Beit Haemek,
Israel). RPMI was purchased from Invitrogen (Carlsbad,CA, USA). Trizol and Prime Script RT were purchased
from Takara (Dalian, China). Matrigel matrix was pur-
chased from BD Biosciences (Biosciences, Bedford, MD,
USA). siRNA was purchased from GenePharma (Shanghai,
China). Antibodies against GAPDH (cat: ab8245), KCNN4
(cat: ab83740), p50 (cat: ab7971), and p65 (cat: ab7970)
were purchased from Abcam(Cambridge, MA, USA). Anti-
bodies against CD68 (cat: sc-393951) and CD206 (cat:
sc-376108) were purchased from Santa Cruz (Santa Cruz,
CA, USA). Antibodies against IL-6 (cat: 1457–1) and IL-8
(cat: 3518–1) were purchased from Epitomics (Burlingame,
CA, USA).
Cell cultures and treatment
LoVo cells were purchased from the Shanghai Cell Bank
of the Chinese Academy of Sciences and then transfected
with PAcGFP-PRL-3 (LoVo-P) or PAcGFP (LoVo-C) using
Lipofectamine2000. Stable clones were selected by cultur-
ing with 600 ug/ml G418 for 3 weeks. THP-1 cells were
obtained from Shanghai Cell Bank of the Chinese Academy
of Sciences. Both LoVo and THP-1 cells were cultured in
RPMI 1640, supplemented with 10% fetal bovine serum
(FBS), 100 mg/ml penicillin, and 100 mg/ml streptomycin.
The cells were incubated at 37°C, 5% CO2 in a humidified
atmosphere. M2-polarized THP-1 cells were generated by
phorbol myristate acetate (PMA) treatment (320 nM/106
cells) for 6 h followed by incubation with IL-4 (20 ng/ml)
for 18 h.
Samples and patients
CRC samples were obtained from 71 patients, who were
admitted to the Department of Gastroenteropancreatic
Surgery of Sun Yat-sen Memorial Hospital, Sun Yat-sen
University from 2005 to 2007. Surgically resected speci-
mens were collected immediately after tumor removal.
All samples were collected with informed consent ac-
cording to the Internal Review and the Ethics Boards
of the Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen
University. The protocol was approved by the Ethics
Committee of Sun Yat-Sen Memorial Hospital.
Flow cytometry
Cells were washed in phosphate buffered saline (PBS),
resuspended and then stained with murine anti-human
CD68 or CD206 for 30 min, then washed and incubated
with PE-conjugated goat anti-mouse secondary antibody.
Cells were analyzed by flow cytometry (BD FACS Cabiler).
M2 macrophage and LoVo cell coculture
1 × 106 M2 macrophage cells were seeded into six-well
plates, while LoVo cells were cocultured with M2 mac-
rophages in upper transwell inserts. After coculturing,
LoVo and M2 macrophage cells were washed and used
for later experiments.
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TNF-α was assayed in the culture supernatant of LoVo-P
or LoVo-C cells using the Quantikine Kit (R&D Sys-
tems, Minneapolis, MN) according to the manufacturer’s
protocol.
Western blot assay
Cells were lysed on ice with RIPA buffer containing 1%
PMSF. Sample protein concentration was determined by
the Bradford assay. Denatured proteins were separated
by 10% or 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis, transferred to polyvinylidene fluor-
ide membranes and then blocked in 5% non-fat milk.
Membranes were washed 3 times with Tris-buffered
saline + 0.1% Tween-20 (TBST), incubated with rele-
vant primary antibodies overnight at 4°C, washed and
incubated for 1 h at room temperature with horseradish
peroxidase-conjugated secondary antibodies. Labeled pro-
teins were visualized by chemiluminescence.
siRNA mediated gene suppression
siRNAs targeting human p50 cDNA and p65 cDNA
were purchased from Shanghai GenePharma. The siRNA




GUGACACGUUCGGAGAATT-3′; KCNN4 sense: 5′-GC
CGUGCGUGCAGGAUUUA-3′; anti-sense: 5′-UAAAU
CCUGCACGCACGGC-3′; Lipofectamine 2000 was used
to transfect siRNA into M2 macrophage according to the
manufacturer’s protocol.
Cell invasion assays
Transwell inserts were used to perform cell invasion as-
says. After coating the upper chamber with Matrigel,
1 × 105 cells in 0.2 ml serum-free RPMI 1640 medium
were added. The lower chamber contained 0.8 ml
medium with 10% FBS. After incubating at 37°C, 5%
CO2 for 24 h, cells that had migrated to the lower cham-
ber were fixed with 4% paraformaldehyde, and stained
with 0.1% crystal violet in methanol, then counted under
a microscope.
mRNA extraction and real time quantitative RT-PCR
Total RNA was extracted using Trizol, and reverse tran-
scribed using PrimeScript RT from 500 ng RNA accord-
ing to the manufacturer’s protocol. Quantitative real-
time RT-PCR was performed using the LightCycler 480
(Roche, Basel, Switzerland) and SYBR Assays (Takara,
Dalian, China). Primers were designed to detect CCL2,
CXCL12, CCL17, CCL18, CCL22, EGF, IL-1, IL-6, IL-8,
IL-10, VEGFA, TGF-β and GAPDH. Oligonucleotide se-
quences of qRT-PCR primers are shown in Table 1. Eachsample contained 1× SYBR Premix Ex TaqTM, 0.2 μM
of each forward and reverse primers and 500 ng tem-
plate cDNA in a final volume of 20 μl. Cycling parame-
ters were set as follows: denaturation at 95°C for 30 s,
followed by 40 amplification cycles (95°C for 5 s and 60°C
for 20 s). For relative quantification, 2−ΔΔCt was used to cal-
culate the fold change in gene expression. All of the experi-
ments were performed in triplicate.
ChIP-qPCR
Chromatin immunoprecipitation (ChIP) assays were per-
formed according to manufacturer’s instructions using
the ChIP assay kit from Thermo Scientific and the NF-κB
antibody from Abcam. Briefly, DNA and proteins were
cross-linked by the addition of formaldehyde (1% final
concentration) 10 min before harvesting, and crosslinking
was terminated by the addition of glycine solution for
5 min at room temperature. After that, the cells were
scraped off the plates, and resuspended in PBS with lysis
cocktail (1% final concentration). The DNA was then
sheared into 0.5–1 kbp fragments using sonication at 20%
amplitude, seven times, each for 30 s. After centrifugation,
the supernatant was precleared by incubation with Protein
A/G beads, adsorbed with salmon sperm DNA at 4°C. The
cleared lysates were then incubated overnight with NF-κB
antibody. Immune complexes were precipitated with pro-
tein A/G beads. Pre-immunized rabbit serum was used as
a negative control, and the supernatant of this reaction
was used as an input control. Immunoprecipitated sam-
ples were incubated at 65°C for 12 h to reverse the cross-
link. DNA was extracted using a DNA extraction kit
(CoWin Biotech, Beijing, China) and qPCR was performed
with the following primers using the SYBR Premix
Ex Taq II kit (Takara, Dalian, China): KCNN4-F: 5′-TCAT
CACTGCGAGCACTTGT-3′ KCNN4-R: 5′-CGAAACC
CAATACGTGTAGACA-3′. A melting curve analysis was
performed at the end of target gene amplification. For rela-
tive quantification, 2−ΔΔCt was used to calculate the fold
change in gene expression. All of the experiments were
performed in triplicate.
Plasmids and recombinants
The plasmids including pGL3-basic, pRL-TK and pGL3-
promoter used for luciferase reporter gene expression
analysis were purchased from Promega Ltd. A 127 bp
fragment comprising −585 to −459 bp upstream of the
KCNN4 transcription start site (TSS), which contained
the predicted NF-κB binding site (CCATACAGGG),
was amplified and inserted into the pGL3-promoter
vector to construct pGL3 − 585/−459 vector. Additionally,
pGL3 − 585/−459-M vector with a mutated NF-κB binding
site (CCCCGGAGGG) in the KCNN4 regulatory region
was constructed. Key regions in all constructs were verified
by DNA sequencing.
Table 1 Oligonucleotide sequence of qRT-PCR primers
Gene Forward primer Reverse primer Amplicon(bp)
CXCL12 5′-CCCGAAGCTAAAGTGGATTC-3′ 5′-TTCAGAGCTGGGCTCCTACT-3′ 112
CCL18 5′-CTCTGCTGCCTCGTCTATACCT-3′ 5′-CTTGGTTAGGAGGATGACACCT-3′ 108
CCL17 5′-AGGGACCTGCACACAGAGAC-3′ 5′-CTCGAGCTGCGTGGATGTGC-3′ 133
CCL22 5′-ATGGCTCGCCTACAGACTGCACTC-3′ 5′-CACGGCAGCAGACGCTGTCTTCCA-3′ 114
IL-6 5′-AATAACCACCCCTGACCCAAC-3′ 5′-ACATTTGCCGAAGAGCCCT-3′ 149
IL10 5′-AACAAGAGCAAGGCCGTGG-3′ 5′-GAAGATGTCAAACTCACTCATGGC-3′ 93
IL-1 5′-TCTGTTCTTGGGAATCCATGG-3′ 5′-TCAGTGATGTTAACTGCCTCCAG-3′ 96
IL-8 5′-AAACCACCGGAAGGAACCAT-3′ 5′-CCTTCACACAGAGCTGCAGAAA-3′ 101
CCL2 5′-AAGATCTCAGTGCAGAGGCTCG-3′ 5′-CACAGATCTCCTTGGCCACAA-3′ 103
EGF 5′-CTTGTCATGCTGCTCCTCCTG-3′ 5′-TGCGACTCCTCACATCTCTGC-3′ 118
VEGFA 5′-ATGACGAGGGCCTGGAGTGTG-3′ 5′-CCTATGTGCTGGCCTTGGTGAG-3′ 91
TGF-β 5′-AAGGACCTCGGCTGGAAGTGC-3′ 5′-CCGGGTTATGCTGGTTGTA-3′ 137
GAPDH 5′-ATCACCATCTTCCAGGAGCGA-3′ 5′-CCTTCTCCATGGTGGTGAAGAC-3′ 112
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TAMs with high endogenous expression of NF-κB were
allowed to grow to 60% confluency in 24-well dishes.
After 24 h, pGL3 − 585/−459, pGL3 − 585/−459-M and
pGL3-basic were transfected into TAM cells using Lipo-
fectamine™ 2000 reagent and incubated for 24 h. Cells
were washed twice, suspended in 100 μl reporter lysis
buffer (Promega) and luciferase activity measured using
the dual luciferase reporter assay system and a GloMax
20/20 luminometer (Promega, Madison, Wisconsin, USA)
according to the manufacturer’s protocol. The Renilla lu-
ciferase vector pRL-TK (Promega, Madison, Wisconsin,
USA) was co-transfected to standardize transfection effi-
ciency in each experiment.
Immunofluorescence staining
For immunofluorescence staining, the specimens were
incubated with mouse anti-hCD68 mAb (diluted 1:100),
rabbit anti-hIL-6 Ab (diluted 1:100) and rabbit anti-hIL-
8Ab (diluted 1:100) at 4°C overnight. Secondary staining
with Alexa-Fluor-555 conjugated donkey anti-rabbit and
Alexa-Fluor-488 conjugated goat anti-mouse secondary
antibodies was carried out at room temperature for
60 min, followed by DAPI nuclear counterstaining for
10 min. Images were taken with a Zeiss LSM 700 laser
scanning microscope (Carl Zeiss) with a core data acqui-
sition system (Applied Precision). For control experi-
ments, primary antibody was substituted with normal
rabbit serum.
Statistics
Statistical analyses were performed using SPSS 13.0
(SPSS Inc, USA). All data are present as the mean ± S.D.
Unpaired Student’s t test and one-way ANOVA were
used, as appropriate, to assess the statistical significantof differences between two groups and three or more
groups respectively. χ2 test was applied to analyze the re-
lationship between IL-6 and IL-8 double-positive TAMs
counts and clinicopathologic features. Kaplan–Meier sur-
vival curves were plotted and log-rank test was carried out.
In all cases, a value of p < 0.05 was accepted as significant.
Results
THP-1 cells differentiate into M2 macrophages with PMA
treatment
M2 macrophages are a type of TAM and are activated
by interleukin-4 (IL-4) produced by CD4+ T cells. THP-
1 cells are a human monocyte cell line often used for
macrophage differentiation. THP-1 cells were grown in
suspension, then treated with PMA (320 nM/1 × 106 cells)
for 6 h with subsequent addition of IL-4 (20 ng/ml) for
18 h (total of 24 h). The cells became larger and adherent,
and exhibited pseudopodia. (Figure 1A). Moreover, PMA-
treated THP-1 cells expressed CD68 and CD206, two sur-
face markers of TAMs (M2 macrophages) (Figure 1B).
PRL-3 induces the expression of KCNN4 in TAMs via
TNF-α
Our previous research has demonstrated that PRL-3 can
induce LoVo cells to secrete TNF-α and enhance the ex-
pression of KCNN4 through activation of the NF-κB
pathway in an autocrine manner. Western blot was used
to detect TNF-α expression in LoVo-P and LoVo-C cells
(Figure 2A). ELISA was used to detect TNF-α in the
culture medium (Figure 2B). The results showed that
TNF-α was highly expressed in LoVo-P cells and was
present in the culture medium. To determine whether
PRL-3 could induce KCNN4 expression in TAMs through
TNF-α in a paracrine manner, LoVo-P and LoVo-C cells
were cocultured with TAMs in transwell chambers. The
Figure 1 THP-1 cells differentiate to M2 macrophages with
PMA treatment. A) Normal conditions of THP-1 (left), and treated
with PMA 320 nM for 6 h with addition of IL-4 20 ng/ml for 18 h
(right). B) PMA/IL-4 treated THP-1 cells showed significant induction
of CD68 (a marker of macrophage differentiation) and CD206 (a marker
of TAMs/M2 macrophages).
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after coculture with LoVo-P cells (Figure 2C). Moreover,
compared with LoVo-C cells, coculture of TAMs with
LoVo-P cells for 6 h and 12 h caused a time-dependent in-
crease in TAM KCNN4 (Figure 2D and E). To determine
whether this increase in expression was dependent on the
paracrine effects of TNF-α production by LoVo-P cells,
TNF-α was neutralized by addition of anti-TNF-α to the
coculture system (Figure 2F). This resulted in reduced ex-
pression of KCNN4 in TAMs (Figure 2G).
NF-κB is capable of binding to the KCNN4 gene promoter
To examine whether the expression of KCNN4 in TAMs
was induced by PRL-3 through the NF-κB signaling
pathway, we pretreated TAMs with BAY11-7082, which
is known to inhibit the activity of NF-κB, and we cocul-
tured the TAMs with LoVo-P cells. The expression of
KCNN4 was clearly decreased when NF-κB activity was
suppressed (Figure 3A). Furthermore, specific siRNAs
were used to silence the expression of p50 and p65
(Figure 3B and C), as they are important for NF-κB
binding. After coculture of siRNA-treated TAMs with
LoVo-P cells for 12 h, the expression of KCNN4 was re-
duced by 62% and 53% after p50 and p65 were silenced,respectively (Figure 3D). To further determine whether
NF-κB regulates KCNN4 expression through binding to
its promoter, we evaluated transcription factor binding
sites in KCNN4 regulatory regions using the JASPAR
database (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl).
An NF-κB recognition site (CCATACAGGG) was discov-
ered in the 5′ regulatory region of the KCNN4 gene, sug-
gesting that expression of KCNN4 may be regulated
by the transcription factor NF-κB. To further explore
whether NF-κB regulates KCNN4 expression through
binding to its promoter, we performed transient transfec-
tion assays in TAMs with KCNN4/pGL3 − 585/−459 re-
porters. The results showed that the luciferase activity of
the reporter system in transfected cells was markedly
higher than that in parental TAMs and TAMs transfected
with the KCNN4/pGL3 − 585/−459-M mutant, in which
the NF-κB binding site was mutated via PCR-directed
mutagenesis (Figure 3E). Moreover, ChIP assays were
used to determine whether RelA/p65, which is one of the
subunits of NF-κB, binds to the promoter of KCNN4.
ChIP was performed using an anti-RelA/p65 antibody. A
127 bp fragment of the KCNN4 sequence was amplified,
indicating that the RelA/p65 transcription factor can dir-
ectly bind to the specific promoter region of the KCNN4
gene (Figure 3F). Together, these results indicate that
NF-κB directly binds to the promoter of KCNN4 and reg-
ulates promoter activity.
TAMs promote the invasive activity of LoVo-P cells
through KCNN4
To further investigate the role of TAMs in the invasive
behavior of LoVo cells, we cocultured TAMs with
LoVo-P cells or with LoVo-C cells. LoVo cell invasion
was detected using a transwell chamber and Matrigel.
When interacting with TAMs, LoVo-P cells showed
greater invasive activity than LoVo-C cells (Figure 4A
and B). To exclude any differences in the invasive activ-
ity that may be caused by the cells themselves, we com-
pared the invasiveness of LoVo-P cells cocultured with
TAMs for 12 h, 24 h or 36 h with LoVo-P cells that were
not cocultured with TAMs, and found that the invasive-
ness of cocultured LoVo-P cells was enhanced by 1.7-fold,
2.4-fold, and 3.3-fold, respectively. However, the invasive-
ness of cocultured LoVo-C cells did not show a significant
increase compared with LoVo-C cells that were not cocul-
tured with TAMs (Figure 4C). Moreover, BAY11-7082 was
used to inhibit the NF-κB signaling pathway in TAMs,
which were then cocultured with LoVo-P. Interestingly,
the invasiveness of the LoVo cells decreased significantly
as the level of KCNN4 in TAMs was reduced (Figure 4D).
Moreover, when p50-siRNA and p65-siRNA were used to
inhibit the expression of KCNN4 channels in TAMs, we
found that the invasive activity of cocultured LoVo-P
cells was significantly inhibited (Figure 4E). These results
Figure 2 PRL-3 induces the expression of KCNN4 by TAMs via TNF-α. A)The expression of TNF-α in LoVo-P cells and LoVo-C cells was detected by
western blot. B) TNF-α expression in the culture medium of LoVo-P and LoVo-C cells was detected by ELISA. C) Western blotting for KCNN4 in TAMs
(Control) and TAMs cocultured with LoVo-C and LoVo-P cells. Bars correspond to the mean ± SD, **p < 0.01, compared with LoVo-P cells. D) TAMs were
cocultured with LoVo-P cells for 0, 6, 12 h to detect the expression of KCNN4. Bars correspond to the mean ± SD, **p < 0.01, compared with TAMs
cocultured for 12 h. E) TAMs were cocultured with LoVo-C cells for 0, 6, 12 h to detect the expression of KCNN4. Bars correspond to the mean ± SD,
#p > 0.01, compared with TAMs cocultured for 12 h. F) Anti-TNF-α was added into the coculture system, and ELISA was used to detect the levels of
TNF-α in the medium. Bars correspond to the mean ± SD, **p < 0.01, compared with LoVo-P cells without anti-TNF-α (Control LoVo-P). G) Western blot
was used to detect the expression of KCNN4 of TAMs with anti-TNF-α in the coculture medium. Bars correspond to the mean ± SD, **p < 0.01, compared
with Control.
Xu et al. BMC Cancer 2014, 14:330 Page 6 of 13
http://www.biomedcentral.com/1471-2407/14/330demonstrate that the invasive ability of LoVo cells induced
by PRL-3 is regulated by the expression of KCNN4 chan-
nels in TAMs.
TAMs promote the invasive activity of LoVo-P cells via
IL-6 and IL-8
To further explore the mechanism by which TAMs pro-
mote the invasion of LoVo cells, qRT-PCR was performedto screen a panel of cytokines related to TAMs. Once the
TAMs were cocultured with LoVo-P cells, the expression
levels of IL-6 and IL-8 mRNA were higher than those in
TAMs cocultured with the LoVo-C cells (Figure 5A). Add-
itionally, western blotting showed that IL-6 and IL-8 pro-
tein levels were significantly increased after TAMs were
cocultured with LoVo-P cells (Figure 5B). To further valid-
ate the important role of IL-6 and IL-8 in LoVo cancer cell
Figure 3 NF-κB is capable of binding to the KCNN4 gene promoter. A) Western blotting for KCNN4 of TAMs that were pretreated with or
without BAY11-7082. Bars correspond to the mean ± SD, **p < 0.01, compared with no BAY11-7082 treatment. B and C) siRNAs were used to
specifically inhibit p50 and p65. Bars correspond to the mean ± SD, **p < 0.01, compared with Control (non-transfected). D) Western blotting
for KCNN4 of TAMs cocultured with LoVo-P cells (Control), and TAMs pretreated with Lipo2000(Lipo), p50-siRNA (p50-si), p65-siRNA (p65-si)
before coculturing with LoVo-P cells. Bars correspond to the mean ± SD, **p < 0.01, compared with Control (non-transfected) and Lipofectamine
2000. E) Luciferase reporter assay demonstrated the influence of NF-κB on KCNN4 promoter activity. TAMs were cotransfected with
KCNN4-promoter-luciferase plus pRL-TK-luciferase; KCNN4-promoter (mut) plus pRL-TK-luciferase; or pGL-3-basic plus pRL-TK-luciferase. Luciferase
activity in cell extracts was analyzed by the Dual-Luciferase Reporter Assay System and normalized using pRL-TK-luciferase activity in each sample.
Bars correspond to the mean ± SD, *p < 0.05, **p < 0.01, compared with TAMs transfected with pGL-3-basic. F) ChIP-qPCR assay confirmed that the
transcription factor NF-κB can specifically bind to the regulatory region of KCNN4 in TAMs. Bars correspond to the mean ± SD, **p < 0.01, compared
with isotype-matched IgG control (IgG).
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8 antibody were used to neutralize IL-6 and IL-8 function.
The addition of the IL-6 and IL-8 antibodies to the cocul-
ture system of TAMs and LoVo-P cells reduced the num-
ber of invasive cancer cells in a dose-dependent manner;
an isotype-matched IgG at 10 μg/ml did not have similar
effects (Figure 5C). To further explore whether KCNN4
channels contribute to the upregulation of IL-6 and IL-8,
KCNN4-siRNAs were transfected into the TAMs. This re-
sulted in the reduction of IL-6 and IL-8 (Figure 5D) and a
concurrent reduction in the number of invasive cancer
cells (Figure 5E). These results suggest that both IL-6 and
IL-8 secreted by TAMs promoted the invasiveness of LoVo
cells induced by PRL-3 through the activation of KCNN4
channels.
TAMs express IL-6 and IL-8 in colorectal cancer
To further explore the expression of IL-6 and IL-8 in colo-
rectal carcinogenesis, immunofluorescence staining was
used to detect the distribution of IL-6 and IL-8 in CRC
samples. Interestingly, we observed that IL-6 and IL-8were only expressed in the stroma and not in the tumor
cells. Next, we further tested whether IL-6 and IL-8 posi-
tive cells in the stroma were TAMs. By performing im-
munofluorescence staining of IL-6, IL-8 and CD68, we
demonstrated that many IL-6 and IL-8 double-positive
cells in the stroma were also CD68 positive (Figure 6A
and B, Additional files 1 and 2). These results suggest
that IL-6 and IL-8 are produced in the stroma of colo-
rectal cancer cells and that TAMs are the major source
of stromal IL-6 and IL-8. Furthermore, we also compared
the number of IL-6 and IL-8 double positive TAMs in
metastatic CRC (stages III and IV) and early-stage CRC
(stages I and II). The number of IL-6 and IL-8-expressing
TAMs in metastatic CRC was 2.28-fold higher than those
in early-stage CRC (Figure 6C). To further evaluate the
clinical relevance of TAMs in CRC, we analyzed their
association with the clinicopathologic status of patients
(Table 2). No significant correlation was observed between
the number of TAMs and age or tumor site of the patients.
However, the number of TAMs was closely associated with
clinical staging and lymph node metastasis of the patients.
Figure 4 TAMs promote the invasive activity of LoVo-P cells through KCNN4. A) Transwell chamber assays for LoVo-P cells and LoVo-C cells
cocultured with TAMs for 0, 12, 24, or 36 h. B) Bars correspond to the mean ± SD, **p < 0.01. The numbers of cells passed through the Matrigel
matrix. C) The ratio of LoVo cells cocultured with/without TAMs. D) TAMs were pretreated with or without BAY11-7082, and then cocultured in
transwell chamber assays with LoVo-P cells. Bars correspond to the mean ± SD, **p < 0.01, compared with no BAY11-7082 treatment. E) Transwell
chamber assays for LoVo-P cells cocultured with TAMs (Control) or cocultured with TAMs pretreated with p50-siRNA, p65-siRNA and Lipofectamine
2000. Bars correspond to the mean ± SD, **p < 0.01, compared with Control (non-transfected) and Lipofectamine 2000.
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and IV; p < 0.001) and lymph node metastasis (p < 0.001)
expressed higher levels of IL-6 and IL-8 double-positive
TAMs, suggesting that IL-6 and IL-8 double-positive
TAMs are related to cancer progression. A Kaplan–Meier
survival curve with a median follow-up period of 50 months
demonstrated that patients with a low IL-6 and IL-8
double-positive TAM count (≤20) survive significantly lon-
ger than those with high IL-6 and IL-8 double-positive
TAM counts (>20) (Figure 6D; p = 0.029).
Discussion
The tumor microenvironment has been shown to be
composed of both of tumor cells and mesenchymal cells,and that the microenvironment itself is involved in
tumorigenesis [12]. Tumor-associated macrophages, or
TAMs, are macrophages that are located in the tumor
environment. There are two types of macrophages, M1
and M2. M1 macrophages have antitumor activities
and can produce TNF-α, whereas M2 macrophages are
a type of TAM that can produce TGF-β and express
CD68 and CD206 surface markers. We used PMA to
induce the transformation of THP-1 monocytes into
M2 macrophages according to described methods [13].
TAMs contribute to tumor progression by releasing a
variety of cytokines, such as VEGF, PDGF and IL-10
[14]. In the tumor microenvironment, autocrine and
paracrine loops, controlled by cytokines and receptors,
Figure 5 M2-polarized TAMs enhance the invasive activity of LoVo cells induced by PRL-3 via IL-6 and IL-8. A-B) The expression of
cytokine profile of TAMs cocultured with LoVo-P cells and LoVo-C cells determined by qRT-PCR (A), and protein by western blotting (B). C) Cell
invasion of LoVo-P/LoVo-C cells was evaluated after plating the cells on the upper cell culture inserts, with culture medium TAMs plated in the
lower chambers in the presence of anti-IL-6/IL-8 antibody at 5 or 10 μg/ml, or an isotype-matched IgG control (IgG). D) The expression ratios for
IL-6 and IL-8 in conditioned medium of TAMs wa determined by western blotting. GAPDH was used as a loading control. E) Similar to (C), LoVo-P
cells were cocultured with TAMs that were untreated (Control), mock transfected (Lipofectamine 2000), or transfected with KCNN4-si. Bars correspond
to the mean ± SD, *p < 0.05, **p < 0.01, compared with Control.
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phages and tumor cells during tumor initiation, pro-
motion, and metastasis [15,16]. Our previous studies
have demonstrated that PRL-3 can promote the pro-
liferation and metastasis of CRC cells through the
autocrine secretion of TNF-α, which induces KCNN4
channel expression by activating the NF-κB signaling
pathway. Considering that TNF-α could act as an autocrineand paracrine cytokine to promote the proliferation
and metastasis of tumor cells [17], we speculated that
there might be a paracrine loop between CRC cell and
TAMs in the tumor microenvironment that is con-
trolled via TNF-α. In this study, we showed that TAMs
participate in the progression of CRC induced by PRL-
3 through the TNF-α mediated-secretion of IL-6 and
IL-8 in a paracrine manner. Moreover, such regulation
Figure 6 Immunostaining for TAMs, IL-6 and IL-8 in CRC tissues from early to late stage. A and B) Confocal microscopy for immunostaining
of stages I and IV CRC tissues with CD68 antibody (green), anti-IL-6 (A, red) and anti-IL-8 (B, red). Cell nuclei were counterstained with DAPI (original
magnification, ×200), (images of high resolution are in the Additional files 1 and 2). C) Quantitative analysis of number of TAMs per field. **p < 0.01,
compared with stage IV. D) Kaplan–Meier survival curve of patients with colorectal cancer with lower (≤20 per view of field, n = 29) and higher IL-6
and IL-8 double positive TAMs counts (>20 per view of field, n = 42; p < 0.05).
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specific inhibitor.
To our knowledge, this is the first report indicating
that KCNN4 channels participate in PRL-3 induced
secretion of IL-6 and IL-8 by TAMs. Previous studies
have demonstrated that KCNN4 channels belong to
the Ca2+-activated potassium channel superfamily, and
the activation of these channels is dependent on con-
formational changes in calcium calmodulin [18]. KCNN4
channels are mainly expressed in peripheral tissues, in-
cluding the hematopoietic system, colon, lung and pan-
creatic tissue, and play an important role in the transport
of substances [19]. Previous research has also revealed
that KCNN4 channels regulate cell cycle progression and
cell growth in human endometrial cancer and prostatecancer cells [20,21]. Our data showed that when LoVo-P
cells were cocultured with TAMs, the expression of
KCNN4 channels was significantly increased, indicating
that transcriptional mechanisms are likely to be respon-
sible for the increased KCNN4 expression. A previous
study revealed that activation protein-1 (AP-1) could regu-
late KCNN4 channel expression in T-cell activation [22].
Our research demonstrated that LoVo-P cells could re-
lease TNF-α and subsequently regulate the KCNN4 ex-
pression of TAMs in a paracrine manner. Consistent with
our hypothesis, ChIP-qPCR and reporter gene assays indi-
cated that NF-κB was required for transcription of the
KCNN4 gene and mediated the transcriptional activation
of KCNN4 channel expression in TAMs when they were
cocultured with LoVo-P cells.
Table 2 Correlation of IL-6 and IL-8 double positive TAMs
counts with clinicopathological status in 71 cases of
colorectal cancer patients
Double positive TAMs counts ≤20 >20 P value
Age 67.5±5.9 68.5±6.9
Gender
Male 15 25 0.515
Female 14 17
Clinical stage
I- II 22 12 <0.001
III-IV 7 30
Lymph node metastasis
Negative 20 8 <0.001
Positive 9 34
Site
Colon 15 24 0.652
Rectum 14 18
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TAMs in tumor metastasis, we still questioned whether
TAMs could enhance the metastasis of tumor cells in-
duced by PRL-3. In this study, when LoVo-P cells were
cocultured with TAMs, invasion was significantly en-
hanced. Moreover, we demonstrated that PRL-3 is im-
portant for the ability of TAMs to enhance LoVo cell
invasiveness, as LoVo-P cells cocultured with TAMs ex-
hibited increased invasiveness compared with LoVo-P
cells that were not cocultured with TAMs. LoVo-C cells
did not exhibit the same features. Additionally, when
TAMs were pretreated with p50/p65-siRNA or BAY11-
7082, the invasive ability of LoVo-P cells was inhibited
and the expression of KCNN4 channels was decreased.
It is possible that the KCNN4 channels of TAMs en-
hanced the PRL-3-induced metastasis of CRC cells.
Previous studies have shown that potassium channels
can regulate the cytokine secretion of human activated
macrophages [23]. We therefore tested whether KCNN4
channels could regulate the cytokine secretion of TAMs.
Our data showed that once LoVo-P cells were cocul-
tured with TAMs, the secretion of IL-6 and IL-8 was sig-
nificantly increased. Moreover, it is notable that the
secretion of IL-10 was also increased significantly. IL-10
is produced mainly by T cells and macrophages and has
a role in immunoregulation. It has been shown that
IL-10 can inhibit the expression of MHC molecules
and costimulatory molecules, and can reduce antigen-
presentation [24]. Besides, IL-10 can also impair secondary
CD8+ T cell responses and thus inhibit tumor immunity
[25]. In addition, it has been shown that TAMs in the
tumor microenvironment not only secret inflammatory
mediators but also have immunoregulatory effects [26].We are therefore curious as to whether IL-10 produced by
TAMs may contribute to the immunosuppressive tumor
environment, and this feature of TAMs will be studied in
our future research. Next, we explored whether KCNN4
channels could regulate IL-6 and IL-8 expression. When
TAMs were pretreated with TRAM-34, the expression
of IL-6 and IL-8 was significantly decreased, compared
with controls, when the TAMs were cocultured with
LoVo-P cells. These observations suggest that KCNN4
channels have the ability to regulate TAM secretion of
IL-6 and IL-8.
The mechanism by which KCNN4 channels regulate
IL-6 and IL-8 expression of TAMs remains to be investi-
gated. It is known that KCNN4 channels in lymphocytes
can maintain a hyperpolarized membrane potential,
thereby facilitating and maintaining the intracellular
Ca2+ levels required for cell proliferation and gene
expression [27,28]. Recent studies have revealed that
intracellular Ca2+ levels regulate the secretion of TNF-α
and IL-6, which play important roles in inflammation
[29]. However, another previous study revealed that a cal-
cium ionophore can inhibit IL-6 and IL-8 expression in
Jurkat T-cells [30]. Further studies are needed to verify
whether the intracellular Ca2+ levels of TAMs can regu-
late the expression of IL-6 and IL-8 and to determine the
underlying mechanism.
Cancer-associated inflammation is known to affect the
proliferation, angiogenesis, and metastasis of tumor cells
[31]. For example, the activation of NF-κB triggers the
production of the inflammatory chemokine IL-8 by
tumor cells [32]. Inhibition of the IL-6 signaling pathway
inhibits tumor development in a colitis-associated car-
cinogenesis model [33]. In our research, the levels of
TAM-derived IL-6 and IL-8 were significantly increased
upon coculture with LoVo-P cells. Using the transwell-
invasion system, IL-6 and IL-8 significantly enhanced the
ability of LoVo-P cells to metastasize, and this response
was attenuated by IL-6 and IL-8 antibodies. These results
suggest that TAM-derived IL-6 and IL-8 induced by
PRL-3 affect the metastasis of tumor cells in a paracrine
manner.
Further confirming this result, and extending it to hu-
man disease, we demonstrated that IL-6 and IL-8 were
mainly expressed by TAMs in CRC tissues. Studies have
shown that serum levels of IL-6 and IL-8 were higher in
CRC patients versus controls, indicating that IL-6 and
IL-8 may be potential targets for CRC [34]. Furthermore,
our data also demonstrated that a high density of TAMs
expressing IL-6 and IL-8 was positively correlated with
tumor stage. Therefore, targeting therapies against IL-6,
IL-8, and KCNN4 channels of TAMs may prevent CRC
liver metastasis through a number of mechanisms, in-
cluding both metastasis prevention and anti-inflammatory
effects.
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Our study demonstrated that IL-6 and IL-8 activity in
TAMs promoted the tumorigenesis of CRC and served
as a mediator of epithelial-stromal interaction. We also
revealed the presence of paracrine loops between PRL-3
and TAMs, which function via TNF-α in the tumor
microenvironment. This regulatory pathway may be a
potential target for the development of new therapeutic
strategies for patients with CRC liver metastasis.
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